ropidoxuridine
Small moleculeexperimental
Clinical trial activity
5 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Oct 26, 2010 (NCT01240577)
Timeline
Indications
Studied for
- Bile Duct Neoplasms · Phase 1
- Brain Neoplasms · Phase 1
- Colonic Neoplasms · Phase 1
- Colorectal Neoplasms · Phase 1
- Esophageal Neoplasms · Phase 1
- Glioblastoma · Phase 2
- Intestinal Neoplasms · Phase 1
- Liver Neoplasms · Phase 1
- Lymphoma · Phase 1
- Neoplasms · Phase 1
- Pancreatic Neoplasms · Phase 1
- Stomach Neoplasms · Phase 1
Mechanism of action
- DNA polymerase nuINHIBITOR
POLN inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
O=c1ncc(I)cn1[C@H]1C[C@H](O)[C@@H](CO)O1- Mol. weight
- 338.1 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Prodrug
Sources
- ChEMBLCHEMBL2103821 ↗
Also known as
- 1-(2-deoxy-beta-ribofuranosyl)-5-iodo-2-pyrimidinone
- 5-iodo-2-pyrimidinone 2' deoxyribonucleoside
- 5-iodo-2-pyrimidinone-2'-deoxyribose
- ipdr
- ipdr
- ipdr
- ipdr
- ropidoxuridine
- ropidoxuridine
- ropidoxuridine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06359379 | Phase 2 | Sep 2, 2024 | Shuttle Pharmaceuticals, Inc. |
| NCT04406857 | Phase 1 | Jan 7, 2021 | National Cancer Institute (NCI), University of Toronto |
| NCT02993146 | Phase 1 | Dec 7, 2016 | Mayo Clinic, National Cancer Institute (NCI) |
| NCT02381561 | Phase 1 | Feb 1, 2016 | National Cancer Institute (NCI), Rhode Island Hospital |
| NCT01240577 | Phase 1 | Oct 26, 2010 | National Cancer Institute (NCI) |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 4 | 4 | 1 | 2010 |
| Mayo Clinic | Academic/Hospital | 1 | 0 | 1 | 2016 |
| Rhode Island Hospital | Academic/Hospital | 1 | 0 | 1 | 2016 |
| Shuttle Pharmaceuticals, Inc. | For profit | 1 | 1 | 1 | 2024 |
| University of Toronto | Academic/Hospital | 1 | 0 | 1 | 2021 |
5 organizations
Page 1 / 1